Related Experiment Video
Updated: Jun 21, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
[Prognostic factors in patients with diffuse large B-cell lymphoma]
Vera Uzurov-Dinić1, Aleksandar Savić, Tanja Lazarević
1Klinika za hematologiju, Klinicki centar Vojvodine, Novi Sad.
Medicinski Pregled
|July 24, 2009
Summary
The international prognostic index and complete remission status significantly impact survival in diffuse large B-cell lymphoma patients. These factors are crucial for predicting outcomes in this aggressive lymphoma.
Area of Science:
- Hematology
- Oncology
- Clinical Pathology
Context:
- Diffuse large B-cell lymphoma (DLBCL) is an aggressive hematologic malignancy with variable prognosis.
- Accurate prognostic markers are essential for guiding treatment strategies and patient management.
- Previous studies have explored various clinical, laboratory, and immunohistochemical factors.
Purpose:
- To investigate the prognostic significance of clinical, laboratory, and immunohistochemical factors in diffuse large B-cell lymphoma.
- To identify key indicators that predict patient survival and treatment response.
Summary:
- A retrospective study analyzed 50 DLBCL patients, examining demographic, clinical, laboratory, and immunohistochemical data.
- International Prognostic Index (IPI) scores and complete remission status were found to be significant predictors of survival.
- Bcl-2 and Ki67 expression, along with treatment type, did not demonstrate a significant influence on survival outcomes.
Impact:
- The findings highlight the importance of the international prognostic index and complete remission status in predicting DLBCL patient outcomes.
- This information can aid clinicians in risk stratification and personalized treatment planning for DLBCL.
- Further research may explore novel prognostic markers to improve therapeutic strategies for DLBCL.